An international study reveals that large language models can summarize electronic health records as effectively, or even better, than medical experts, promising significant time savings and enhanced patient care.
Biogen CEO Viehbacher undaunted by Lilly’s impending Alzheimer’s therapy, saying it will ‘expand’ market
NEW YORK — Facing a challenging launch for the Alzheimer’s drug Leqembi, Biogen CEO Chris Viehbacher said he would welcome competition from other companies, including